Navigation Links
AFFiRiS Begins Development of a Parkinson's Vaccine
Date:12/11/2008

VIENNA, Austria, December 11 /PRNewswire/ -- AFFiRiS has started pre-clinical development of a Parkinson's vaccine. The vaccine, known as PD01, can be used to target a specific protein that is closely associated with the causes of this degenerative neurological disease. Excellent product candidates from discovery studies have prompted the company to file a patent application and proceed immediately with development. Similarly positive results from external assessments impelled the Austrian Research Promotion Agency (FFG) to provide considerable financial funding for the project. The vaccine is based on the company's AFFITOME technology, which, among other things, has already been used to develop two Alzheimer's vaccines, which are currently both in phase I clinical testing.

AFFiRiS, based in Vienna, Austria, today announced the start of the pre-clinical development of its first Parkinson's vaccine PD01. The vaccine will be investigated for efficacy ("proof of concept") in Parkinson models. On successful conclusion of this preclinical evaluation, initial clinical testing could start in 2010/11. The Parkinson's vaccine specifically targets the alpha-synuclein (alpha-syn) protein, which is considered to be a key contributory element in Parkinson's disease.

Although all details of the disease are not yet fully understood, there is clear scientific evidence that the concentration and enrichment of alpha-syn in the brain are contributing factors in the progression of Parkinson's disease. Therefore, reducing the alpha-syn burden in the brain should have a positive impact on the course of the disease - a hypothesis that was recently confirmed by the results of U.S. researchers working on animal models.

The Parkinson's vaccine from AFFiRiS has been developed to delivery efficacy in combination with an excellent safety profile, as Dr. Walter Schmidt, CEO of AFFiRiS, explains: "Alpha-syn is an attractive targ
'/>"/>

SOURCE AFFiRiS GmbH
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. AFFiRiS: Milestone Reached in Clinical Trial of Alzheimers Vaccine
2. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
3. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
4. Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
5. Patient Recruitment Begins in India for Phase 3 Diabetes Trial
6. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
7. Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins
8. Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate
9. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
10. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
11. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2New Swine Flu Strain Found in Brazil 3A Report 49266 1New Swine Flu Strain Found in Brazil 3A Report 49266 2New Swine Flu Strain Found in Brazil 3A Report 49266 3New Swine Flu Strain Found in Brazil 3A Report 49266 4New Swine Flu Strain Found in Brazil 3A Report 49266 5New Swine Flu Strain Found in Brazil 3A Report 49266 6New Swine Flu Strain Found in Brazil 3A Report 49266 7New Swine Flu Strain Found in Brazil 3A Report 49266 8New Swine Flu Strain Found in Brazil 3A Report 49266 9New Swine Flu Strain Found in Brazil 3A Report 49266 10New Swine Flu Strain Found in Brazil 3A Report 49266 11New Swine Flu Strain Found in Brazil 3A Report 49266 12Fathers 26apos 3B Hearing Affects Family Function and Fiscal Health 49263 1Fathers 26apos 3B Hearing Affects Family Function and Fiscal Health 49263 2Fathers 26apos 3B Hearing Affects Family Function and Fiscal Health 49263 3Fathers 26apos 3B Hearing Affects Family Function and Fiscal Health 49263 4MedNet Solutions Unveils New Naming and Functionality for its Flagship EDC eClinical Offering 12678 1MedNet Solutions Unveils New Naming and Functionality for its Flagship EDC eClinical Offering 12678 2